Horcents, you missed my point and this seems to be intentional on your part.
As you know, I used the China example as an example of how "time does not prove if everything is true or false."
Sorry but I have to say your zeal to argue with me has crossed over into simply wasting my time.
selling april puts big in here im taking your money again and again .the for calls are now .30 lol this was a great month for selling calls and puts
" The cause in this case could be Merck would like to have an easy entry to the LTC market through a proven sales force."
Okay that's an interesting thought.
Okay, I thought about it.
Merck has a huge sales force.
Merck could easily train and send some of their reps to do what Avanir's LTC reps are doing.
Merck does not have to buy Avanir to continue to have their products promoted at LTC facililties. Neither does Merck have to buy stock in Avanir or buy Avanir or partner with Avanir in Europe or the U.S.
There is no compelling issue for Merck to do ANY of that.
If Merck wants to expand the promotion of other products of theirs into the LTC market they could most easily make another contract with Avanir.
Or again, Merck could tell their reps to go to LTC facilities.
How easy is that?
Rim/Ray/RS who cares. You are good at pretending to be civil, yet fond of accusing others of being dishonest. Those on the board can make up their own mind about what you or I represent.
"perhaps going down to the moderate mild end of TRD, N may be the better option."
I think usually, treatment-resistant depression is severe depression.
I don't think mild or even moderately severe treatment resistant depression justifies the possible risk of intravenous ketamine given what is known now. Maybe after more experience with intravenous ketamine it will be shown not to be overly dangerous, or maybe not, I don't know.
So I do not think intravenous ketamine is an option for mild to moderate depression now.
It is premature to even discuss Dex/quin as a primary treatment for depression. There isn't even a proof of concept.
It has to be studied to have an opinion.
It makes some sense to try dex/quin off-label for severe treatment resistant depression after a good response to ketamine to try to prevent relapse but the results should be reported in a medical journal and there should be a larger study of ketamine itself and a study of ketamine plus dex/quin afterward versus ketamine alone.
The important points are treatment resistant depression treated with ketamine is a very small possible market and it has to be investigated further if there is any possible market there, much less if dex/quin will prevent relapse in patients who do have a good temporary response to ketamine.
Please realize how premature this discussion is. While ketamine is exciting for the possible treatment of a few severely sufferring individuals, it may not pan oput and there is really nothing for Avanir longs to be excited about. It not an investable idea at this point.
Regardless if Avanir puts it out as a bullet on a slide presentation.
"You have to remember Ray loves the new Remove feature"
You are intentionally confusing me with Rim.
Dishonest of you to do that.
Rim says he likes to use the Remove feature for people who harass him.
I have only used the "Remove" feature to fix significant typos. I remove posts when I see a significant typo and repost it a minute later with the typo fixed.
Thank you for the reply “All clinical depression is described as Major Depression”
Could be confusing but at the same time simple which may give a half way answer to the 1 in 6 result and the dosing of which we do not know, I’m encourage but that.
At one end of the TRD scale we have the severe TRD down to moderate at the other end. (Please bare with me I’m no expert). I’m giving consideration to ketamine should be used for only severe (although the professor has reported an excellent result for N) and perhaps going down to the moderate mild end of TRD, N may be the better option. I’m not sure how the trial is going as I have not seen an update for a good while. If I recall right it ends next year and we shall know more then, perhaps we shall get some feed back before hand.
Just touching on costs did you see what they charged for one treatment of K
As I said to you both, I never said Nuedexta would never get FDA approval.
You know that I explained that but you choose to continue to use his false characterization of what I posted.
There's your problem again.
But as you knew, as he pointed out to you, Justien posted, "what's preventing you from getting your own Pacer account? It's free, anyone can do it..... And even you can afford the page costs, it's really next to nothing. "